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ABSTRACT
Aim:
Depression experienced by people with colorectal cancer (CRC) is an important clinical problem 
affecting quality of life. Recognition at key points in the pathway enables timely referral to 
support. This study aimed to examine depression pre- and 5 years post-surgery to examine its 
prevalence and identify determinants.
Methods:
The ColoREctal Wellbeing (CREW) study is a prospective UK cohort involving 872 adults with non-
metastatic CRC recruited before curative-intent surgery. Questionnaires completed pre-surgery, 
and 3, 9, 15, 24, 36, 48 and 60 months post-surgery, captured socio-demographics, assessed 
depression (Centre for Epidemiologic Studies Depression Scale, CES-D) and other psychosocial 
factors. Clinical details were also gathered. We present prevalence of clinically significant 
depression (CES-D≥20) over time and its predictors assessed pre-surgery and 2 years post-
surgery.
Results:
Pre-surgery, 21.0% of the cohort reported CES-D≥20 reducing to 14.7% 5 years post-surgery. Pre-
surgery risk factors predicting subsequent depression were clinically significant depression and 
anxiety, previous mental health service use, low self-efficacy, poor health, having neoadjuvant 
treatment and low social support. Post-surgery risk factors at 2 years predicting subsequent 
depression were clinically significant depression, negative affect, cognitive dysfunction, 
accommodation type and poor health.
Conclusions:
Depression is highly pervasive in people with CRC, exceeding general population prevalence 
across follow-up. Our findings emphasise the need to screen and treat depression across the 
pathway. Our novel data highlight key risk factors of later depression at important and 
opportune time points: pre-surgery and the end of routine surveillance. Early recognition and 
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WHAT DOES THIS PAPER ADD TO THE LITERATURE?
Depression in people living with colorectal cancer is an important clinical problem. Our study 
shows that the prevalence of depression exceeds general population prevalence over time. It 
also highlights risk factors of later depression at important time points (before surgery and end 
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INTRODUCTION
Depressive disorders are one of the highest contributors to global disease burden, affecting 4% 
of people(1). Its prevalence is greater in people living with cancer (rates range between 8 and 
27%(2)) and thus is a clinical and policy priority(3). In people living with colorectal cancer (CRC), 
the prevalence of depression is also greater when compared to the general population with rates 
reaching 37%(4-7). Depression in people living with cancer is associated with poor quality of life 
(QoL)(8), reduced adherence to treatment(9), reduced survival(10) and is associated with an 
increased risk of suicide(11). More specifically, people with CRC and depression have poorer QoL, 
health status and wellbeing after diagnosis and surgery(5, 7).
Despite this, depression is often not identified in people with cancer and few are treated(6); 
possibly due to a range of factors associated with underreporting mental health issues (e.g. 
stigma)(12). Timely recognition and referral to support and intervention is recommended in 
clinical guidelines for depression internationally(13) with UK guidelines recommending targeting 
screening in people at most risk(14). However, determinants of depression in people living with 
cancer are poorly characterised(15) with calls for more evidence in people with CRC(16). 
Identification of people most at risk also informs intervention development, reduces disease 
burden and improves planning of psychosocial care resources(17).
Several determinants of depression in people with CRC have been described including: 
female gender(4, 18, 19), low socio-economic status(20), higher stage disease(21), receipt of 
neoadjuvant and adjuvant treatments(22), and low social support(23, 24). Findings related to age 
are inconsistent(19, 21, 25) but may be owed to sample characteristics (e.g. recruitment of an 
older sample(25)). Depressive symptoms in people with CRC are also reported to reduce over 
time(4, 5) but much research is cross-sectional(16). We conducted a scoping review and found 
that no published longitudinal studies in people with non-metastatic CRC have examined pre-
surgery risk factors associated with reporting depression up to 5 years post-treatment (Appendix 
1). 
UK clinical guidance recommends pre- and post-treatment as key time points to appraise 
psychological outcomes in people living with cancer(26). Assessment, close to diagnosis, allows 
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26). Early screening is also encouraged due to its benefits: improving treatment adherence, 
reducing burden on health services and patients, enhancing communication between clinical 
teams and patients, and more timely referral to support(17, 27). Addressing psychological 
outcomes post-treatment gives patients the opportunity to reflect on the impact and 
psychosocial concerns following the intense scheduling of cancer treatment(15, 26). Post-
treatment CRC surveillance is valuable to provide reassurance as patients feel greater concern 
when its frequency decreases(28), possibly due to reduced contact with clinical teams(29), so we 
highlight this time point as important to consider. In the UK it is recommended that routine 
surveillance appointments cease after 2 years(30) with some variation in international 
guidelines(31).
This paper presents analysis from the ColoREctal Wellbeing study (CREW)(32), a UK 
prospective cohort investigating factors associated with recovery of health and wellbeing 
following CRC. Data were collected before and at regular intervals up to 5 years post-surgery. 
Data comprised of socio-demographic, clinical information, and patient-reported outcomes 
examining a selection of psychosocial variables (including depression) informed by a conceptual 
framework of recovery following cancer diagnosis and treatment(33). The analysis assesses 
‘clinically significant levels’ of depression via self-reporting and whilst this is not a ‘clinical 
diagnosis’ of depression, which requires a comprehensive assessment accounting contextual 
factors(14), the cut-off used has high concordance with psychiatric interviews(34) suggesting the 
experience of high levels of depressive symptomology(35). This paper:
(1) describes the prevalence of clinically significant levels of depression from pre-surgery up 
to 5 years post-surgery; and,
(2) given the levels of depression pre-surgery and at 2 years post-surgery, identifies which 
characteristics are associated with subsequent clinically significant levels of depression up 
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METHODS
Study sample
CREW is a prospective cohort study of adults (≥18 years) with non-metastatic colorectal cancer 
(Dukes’ stage A-C) treated with curative-intent surgery. Inclusion and exclusion criteria are 
published elsewhere(32).
Data collection
Details of study procedures are previously reported(32). Eligible participants were recruited from 
29 UK National Health Service (NHS) centres between November 2010 and March 2012. 
Participants consented and completed questionnaires before surgery (baseline). Follow-up 
questionnaires were mailed at regular intervals: 3, 9, 15, 24 months and annually up to 5 years 
post-surgery. Clinical and treatment information was gathered from NHS medical databases at 
participating centres. Ethical approval was granted by the UK NHS NRES Committee South 
Central - Oxford B (REC ref: 10/H0605/31). Information collected in the study did not inform the 
care of the participants involved due to the study design and anonymisation of the data.
Measures
Patient-reported depression was captured using the 20-item Centre for Epidemiologic Studies 
Depression Scale (CES-D)(36). Higher scores indicate greater levels of depression (range 0-60). A 
recent meta-review demonstrated that CES-D was responsive to change and suitable for 
screening for depression in people with cancer(37).
A score of ≥20 has previously been used in studies involving people with cancer to define a 
‘clinically significant level’ of depression(38) and has been shown to be highly concordant with 
psychiatric interviews(34). A recent meta-analysis examining the screening accuracy of CES-D 
noted the ≥20 cut-off to be more appropriate when compared to the standard ≥16 cut-off(35). 
Thus the ≥20 cut-off was selected as an indicator of a clinically significant levels of depression for 
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Determinants/Covariates
Table 1 lists the validated patient reported outcome measures, socio-demographic questions and 
clinical information captured pre-surgery and 2 years post-surgery which were used as covariates 
in the analyses. Covariates are presented according to the conceptual framework domains(33) 
and the rationale for each measure is provided elsewhere(32). Validated measures were 
repeated at every time point unless otherwise indicated. Selection of covariates, including EORTC 
subscales, were informed by our scoping review (Appendix 1). Alongside depression, 
accommodation type, health status (EQ-5D), age and ethnicity was found to be significantly 
associated with participant attrition in the CREW study(39) and were included in the model to 
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Statistical analysis
Total CES-D score was summarised at each time point using its median and interquartile range to 
examine changes over time. The number and proportion of participants reporting clinically 
significant levels of depression (CES-D≥20) were also assessed over time.
Two multivariable logistic regression models were fitted to predict clinically significant levels 
of depression up to 5 years after surgery (Appendix 2): Model 1 included depression together 
with other covariates collected pre-surgery (baseline); Model 2 included depression together 
with other covariates collected at 2 years post-surgery. Multicollinearity was assessed in each 
model using the Variance inflation factor (VIF). The VIF ranged from 1.05 to 2.18 for Model 1 and 
from 1.08 to 2.51 for Model 2. VIF below 10 indicates that there was no evidence of 
multicollinearity in our models.
Missing data were imputed according to published guidelines for the measures selected. If 
unavailable, these were omitted from the final model. Number of comorbidities were first 
assessed at 3 months but were included in Model 1 due to its stability over time(40).
A population-average approach was applied to account for the time-varying nature of the 
binary outcome, where each model was adjusted for the clustering of observations within the 
participants(41). Regression analyses were based on a backwards elimination of statistically non-
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RESULTS
Sample characteristics
One thousand and eighteen participants were recruited into CREW and 872 consented to 
questionnaire follow-up. Figure 1 presents the participant flow over follow-up; full details of 
study recruitment and descriptive statistics are published elsewhere(39, 42). The sample was 
representative of the eligible patients treated during the recruitment period(39, 42). Table 2 
shows demographic and clinical characteristics of the 741 participants who returned a baseline 
questionnaire and had completed the CES-D with a mean age of 67.54 (SD=10.26). Over 54% of 
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Depression over time
At baseline (pre-surgery), people who were women, single, living in rented accommodation and 
had previously used mental health services, were more likely to report clinically significant CES-D 
scores (Table 2). 
Median scores peaked before surgery at 12.0 (IQR=11.7) and decreased to 9.5 (IQR=12.0) at 5 
years (Table 3). Similarly, the proportion of participants reporting clinically significant levels of 
depression also peaked pre-surgery at 21.0% and reduced to 14.7% at 5 years (Table 3). Overall, 
303 participants (34.8%) reported clinically significant depression at least once during their 5 
years of follow-up.
Pre-surgery determinants of clinically significant levels of depression
Table 4 presents only the significant pre-surgery factors associated with the likelihood of 
reporting a clinically significant level of depression. 
Participants who reported clinically significant levels of depression pre-surgery had a higher 
risk of being depressed over follow-up (OR=3.44, 95% CI=2.18–5.45); this was similar for highly 
anxious people (OR=1.82, 95% CI=1.15–2.87). People with a low level of self-efficacy (confidence) 
to manage the consequences of a chronic condition were also at a greater risk of reporting 
clinically significant levels of depression. Conversely, people who reported ‘full’ social support 
(OR=0.41, 95% CI=0.23–0.74) had lower odds of reporting clinically significant depression and 
this was also the case for ‘perfect’ health status (OR=0.42, 95% CI=0.24–0.75).
Greater risk of reporting clinically significant levels of depression up to 5 years post-surgery 
were found in people who underwent neoadjuvant treatment (OR=2.99, 95% CI=1.75–5.09) and 
in those who reported previous use of mental health services (OR=3.33, 95% CI=1.48–5.24) 
compared to those who did not. People with rectal cancer also had lower odds of having clinically 
significant depression compared to those with colon cancer (OR=0.55, 95% CI=0.35–0.87).
Both age and domestic status were found to be statistically significant predictors of 
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risk of experiencing clinically significant levels of depression when compared to people aged 61-
70 (OR=0.50, 95% CI=0.26–0.97), although this was not evident when compared to other age 
groups (Table 4). The odds of reporting clinically significant levels of depression were two times 
higher for people who did not have a partner (OR=2.02, 95% CI=1.32–3.09) compared to those 
who did.
Determinants 2-years post-surgery
Table 5 presents only the significant predictors, captured at 2 years post-surgery, of clinically 
significant levels of depression reported at 2 years. Similar to pre-surgery, participants reporting 
clinically significant levels of depression at 2 years were at greater risk of subsequent depression 
up to 5 years (OR=3.14, 95% CI=1.41–7.04). Those who had higher scores for negative affect were 
also at greater risk (OR=1.21, 95% CI=1.08–1.36). 
People reporting problems with cognitive function (OR=2.21, 95% CI=1.03–4.77) and poorer 
wellbeing (OR=2.40, 95% CI=1.25–4.61) at 2 years also had higher odds of experiencing clinically 
significant depression later. Participants who did not own their accommodation were also at 
greater risk of reporting clinically significant depression (OR=2.38, 95% CI=1.23–4.62).
In contrast, the risk of reporting clinically significant levels of depression was lower amongst 
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DISCUSSION
This is the first prospective cohort to examine the prevalence and risk factors associated with 
clinically significant levels of depression in people with non-metastatic CRC assessed pre- and up 
to 5 years post-surgery. Our results reveal that clinically significant levels of depression remain a 
long-term problem for a considerable proportion of people, despite median CES-D scores 
reducing over time from initial diagnosis. These results are consistent with previous findings(4, 
5). For example, our prevalence rates across each time point occur within the range observed by 
cross-sectional studies of people living with CRC (7−37%(4-7)) and are considerably higher 
compared to the median prevalence found in the general population (CES-D≥20; 11.8%)(35).
The novelty of this study is the investigation of risk factors of clinically significant levels of 
depression at two key time points in the cancer care pathway as recommended by UK clinical 
guidance(26): close to diagnosis (pre-surgery) and when post-treatment routine surveillance 
ends (2 years post-surgery). Identifying risk factors improves planning of psychosocial care and 
informs intervention development(17). We identified several pre- and post-surgery risk factors of 
depression consistent with previous work(4, 5, 7, 19, 20, 22-25). 
Importantly, our findings underscore the need for depression screening close to diagnosis 
with clinically significant levels pre-surgery identified as a risk for later depression. Early 
screening has been shown to positively impact care by improving more timely referrals for 
psychological intervention(17, 27). Our analysis at 2 years post-surgery also suggests the need for 
assessment of depression and depressive symptomology (negative affect) when post-treatment 
surveillance ends. Regular appraisal of psychological needs throughout the pathway aligns with 
recent emphasis of risk stratification in the UK NHS Long Term Plan to inform personalised care 
for people with cancer and facilitate referral to appropriate levels of care(43). Psychosocial 
interventions for people with colorectal cancer have been reported to be beneficial in improving 
depression and anxiety symptomology, as well as QoL (44, 45). Novel strategies for follow-up 
have been tested in Australia(46) , Canada(47) and are being considered in the USA(48).  Such 
strategies can help target specialist resources as these become increasingly scarce(48). 
Innovative models of psychological screening and care (e.g. stepped-care and nurse-led 
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symptoms, improve QoL for people with a depressive or anxiety disorders and are cost-
effective(49, 50). Internationally, variability in models and approaches to survivorship care and 
complexity in reimbursement for psychosocial and integrated care make implementation a 
challenge(51).
Our pre-surgery analysis also highlights at-risk groups to whom we should direct depression 
screening. People undergoing neoadjuvant treatment commonly face more complex surgery, 
stoma formation, additional side effects, and increased treatment time length(22) which can 
explain our findings and so attention should focus on this group. People with rectal cancer had a 
lower risk of clinically significant depression over time but no previous CRC studies have reported 
tumour site as a significant predictor of depression(16). This relationship was also unexpected as 
people with rectal cancer often have complex treatment regimens (including neoadjuvant 
treatment)(52) which may impact psychological outcomes, particularly those who later have a 
permanent stoma(53). One possible explanation could be that a more complex treatment 
pathway may result in greater contact with clinical teams and this may improve perceptions of 
support(29, 54) that could help to reduce depression symptomology. Nevertheless, this finding 
requires further investigation.
Our analysis further recommends that depression screening should target people with a 
history of mental health problems or with psychological comorbidities (e.g. anxiety). This is 
unsurprising as levels of anxiety tend to peak close to diagnosis(55) and commonly co-occurs 
with depression(8). 
The value of assessing self-efficacy and social support early in the pathway was highlighted by 
our pre-surgery analysis. This is important given the increasing role of self-management for 
people with cancer(56); thus confidence to manage consequences of cancer and its treatment 
need to be assessed early on. Assessing the level of social support at the point of diagnosis is 
imperative given its importance for depression outcomes and later QoL(23).
Our analysis at 2 years post-surgery highlighted other at-risk groups in whom assessment and 
support for depression may be helpful. People with cognitive difficulties post-surgery were at 
greater risk of later depression which is important as cognitive dysfunction is a commonly 
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difficult to delineate cognitive dysfunction as a result of cancer treatment or as a symptom of 
depression and/or anxiety(58). Type of accommodation (rented or other) was also highlighted as 
a risk factor but this specifically has not been reported previously. It could be used as a descriptor 
of socio-economic status (SES) which has been noted to be a risk factor for anxiety, depression 
and distress in people with cancer(20, 59). This highlights the need for additional support for this 
group as low SES may indicate a low availability of resources important for coping which may 
result in poorer psychological outcomes(59).
Study strengths include the scale and representative nature of the CREW sample with over 
91% of all eligible patients approached to participate(39, 42). Loss to follow-up is expected in 
cohort studies but our response rates remained high up to 5 years (Figure 1; 71%). Participants 
who withdrew by 5 years were more likely to report clinically significant depression, were ≥80 
years of age, did not own accommodation (renting or other) and were of non-white ethnicity at 
baseline(39). Therefore, our findings may underestimate the true prevalence of depression 
among the CRC cancer survivors in the UK. Additionally, our sample represents patients from one 
type of healthcare system (the UK NHS) whereby access and provision of specialist services are 
universal and free at the point of delivery.
Patient-reported depression may not account for contextual factors considered in diagnostic 
interviews(14). Nevertheless, the cut-off used suggested clinically significant levels of depressive 
symptomology(35) and is highly concordant with psychiatric interviews(34). High prevalence of 
depression over time may be attributed to its undertreatment(6). However, due to a high level of 
missing data, as a result of poor self-report of health service use in CREW, we were unable to 
examine use of psychological treatment which may explain our findings. We examined our 
mental health service use data in a bivariate analysis with CES-D scores for interest (Appendix 3). 
Scoping of the literature (Appendix 2) identifies this is as one of the first studies to include a 
pre-surgery assessment on a range of socio-demographic, psychosocial and clinical factors and 
the only one to collect data up to 5 years later to examine risk factors of clinically significant 
levels of depression. The importance of this work is highlighted by the dearth of evidence 
examining the long-term psychological impacts in people living with and beyond cancer(3), 
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impacts of cancer and its treatment has been identified as a Top 10 research priority in the 
UK(60) and our analysis contributes knowledge to this for two crucial time points in the CRC care 
pathway.
In summary, our results indicate that depression is an enduring problem in people with non-
metastatic CRC even at 5 years after surgery. Before surgery it affects 1 in 5 people and 1 in 7 
people at five years after surgery, both of which are higher than reported in the general 
population. Our findings clearly highlight the need for screening for depression across the 
pathway to improve depression outcomes in the long-term. Early screening should be focussed 
on those with mental health histories, high levels of anxiety, low self-efficacy, poor health status, 
and low levels of support, whilst clinicians should also monitor people who undergo neoadjuvant 
treatment. The end of routine oncology surveillance is also an opportune time to assess 
depression symptoms, especially as frequency of contact with clinical teams decreases. At this 
time point, assessment should focus on people with poor health, a lower SES and problems from 
treatment (e.g. cognitive dysfunction). Depression in people living with cancer is associated with 
poor health and wellbeing and has an impact on survival and adherence to treatment, early 
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Figure 1: CREW study participant flowchart
NOTE
Participants who were not sent a questionnaire because of mental capacity issues or through 
administrative error remained eligible for the questionnaire at the next time point. 
Definitions: Full consent: participants consented to questionnaire follow-up and the collection of medical 
details; Reduced consent: participants consented to the collection medical details only.
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Table 1: CREW study measures presented by conceptual framework domains(33) for regression 
analysis
















Number of comorbidities‡ Self-reported measure(40)
Clinical factors
Previous use of mental health services§
Domestic status
Life Events





Medical Outcomes Study - Social Support Survey 
(MOS-SSS)(63)
Self-efficacy for Managing Chronic Disease (SEMCD) 
scale(64)Self-efficacy




Positive and Negative Affect Schedule Short Form 
(PANAS-SF)(66)
State anxiety¶ State-Trait Anxiety Inventory, State scale (STAI-S)(67)
Wellbeing Personal Wellbeing Index–Adult (PWI-A)(68)
Psychosocial 
outcomes
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Domain Characteristic of interest Measure
Quality of Life (QoL)‡
Quality of Life in Adult Cancer Survivors (QLACS) 
scale(70):
Cancer-Specific Summary Score (QLACS-CSS), Benefit of 
Cancer (QLACS-BC)
Symptoms & Functioning‡
European Organization for Research and Treatment of 
Cancer quality of life measure (EORTC QLQ-C30)(71):
Function scales: Physical, Emotional, Cognitive, Social
Symptom scales: Fatigue, Pain, Insomnia, Financial 
Worry
NOTE
† To avoid imprecise estimates from the low counts in the regression analyses two or more groups were merged 
together: Unemployed and retired (Employment status); renting and other (Accommodation type); Stages C1 and C2 
(Dukes’ stage); radiotherapy, chemotherapy and both (Neoadjuvant treatment; Adjuvant treatment)
‡ Collected from 3 months onwards. Selection of EORTC subscales was informed by previous work involving people 
with CRC(7, 22, 24, 25).
§ Self-reported at baseline only. 
¶ We used a cut-off of ≥40 to indicate a clinically significant level of anxiety(72). 
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Table 2:  Sociodemographic and clinical information comparisons of CES-D<20 and ≥20 reported at 
baseline (N=741)







Age groups, years    
50 or younger 47 (6.4%) 32 (68.1%) 15 (31.9%) .073
51-60 113 (15.3%) 83 (73.5%) 30 (26.5%)
61-70 285 (38.6%) 236 (82.8%) 49 (17.2%)
71-80 217 (29.4%) 173 (79.7%) 44 (20.3%)
81 or older 77 (10.4%) 58 (75.3%) 19 (24.7%)
Gender
Male 440 (59.4%) 373 (84.8%) 67 (15.2%) <.001
Female 301 (40.6%) 210 (69.8%) 91 (30.2%)
Ethnicity
White British 623 (92.7%) 491 (78.8%) 132 (21.2%) .898
Other ethnic group 49 (7.3%) 39 (79.6%) 10 (20.4%)
Deprivation (IMD) quintile
1st quintile (least deprived) 146 (20.1%) 123 (84.2%) 23 (15.8%) .086
2nd quintile 150 (20.6%) 123 (82%) 27 (18%)
3rd quintile 142 (19.5%) 113 (79.6%) 29 (20.4%)
4th quintile 136 (18.7%) 99 (72.8%) 37 (27.2%)
5th quintile (most deprived) 153 (21%) 114 (74.5%) 39 (25.5%)
Domestic status
Married / Living with partner 524 (71.1%) 430 (82.1%) 94 (17.9%) <.001
Single / Widowed / Divorced / Separated 213 (28.9%) 150 (70.4%) 63 (29.6%)
Employment status
Employed 201 (27.3%) 158 (78.6%) 43 (21.4%) .980
Unemployed / Retired 535 (72.7%) 421 (78.7%) 114 (21.3%)
Accommodation type
Owner occupied 589 (79.9%) 473 (80.3%) 116 (19.7%) .021
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Previous use of mental health services
No 670 (94.5%) 536 (80%) 134 (20%) <.001
Yes 39 (5.5%) 22 (56.4%) 17 (43.6%)
Tumour site
Colon 475 (64.4%) 374 (78.7%) 101 (21.3%) .911
Rectal 263 (35.6%) 208 (79.1%) 55 (20.9%)
Dukes’ stage
A 109 (14.7%) 93 (85.3%) 16 (14.7%) .335
B 391 (52.8%) 303 (77.5%) 88 (22.5%)
C (C1 & C2) 229 (30.9%) 178 (77.7%) 51 (22.3%)
Could not be determined‡ 11 (1.5%) 9 (81.8%) 2 (18.2%)
Neo-adjuvant treatment (any type)
No 592 (80.7%) 465 (78.5%) 127 (21.5%) .649
Yes 142 (19.3%) 114 (80.3%) 28 (19.7%)
Surgery type§
Laparoscopic 401 (54.3%) - - -
Open 299 (40.5%) - -
Not available 38 (5.2%) - -
Adjuvant treatment (any type)§
No 477 (64.6%) - - -
Yes 261 (35.4%) - -
Stoma§
No 262 (35.9%) - - -
Yes 468 (64.1%) - -
Number of comorbidities¶
0 168 (27.6%) 143 (85.1%) 25 (14.9%) .055
1 194 (31.9%) 160 (82.5%) 34 (17.5%)
2 144 (23.6%) 107 (74.3%) 37 (25.7%)
3+ 103 (16.9%) 78 (75.7%) 25 (24.3%)
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* Chi-square, χ2
† Other accommodation includes: Temporary accommodation, living in residential or nursing home, living with 
others (e.g. friends or family)
‡ Dukes’ stage could not be determined for 11 Full Consent patients with small tumours following neo-adjuvant 
therapy
§ Captured from the medical records after Baseline
¶ Self-reported at 3-month
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Table 3: Descriptive statistics for the CES-D score and clinically significant level of depression 
(CES-D≥20) at each time point from pre-surgery to 5 years post-surgery
Pre-surgery Post-surgery
Time point
Baseline 3mo 9mo 15mo 24mo 36mo 48mo 60mo
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Table 4: Multivariable logistic regression model of clinically significant depression (CES-D≥20) up 
to 5 years post-surgery, significant covariates collected pre-surgery (baseline)






50 or younger REF - -
51-60 0.50 0.22 – 1.10 .086
61-70 0.50 0.26 – 0.97 .040
71-80 0.55 0.27 – 1.13 .103
Socio-demographic factors
81 or older 0.77 0.33 – 1.80 .550
Tumour site
Colon REF - -
Rectum 0.55 0.35 – 0.87 .011
Neoadjuvant treatment
None REF - -
Yes, any therapy 2.99 1.75 – 5.09 < .001
Previous use of mental health services
No REF - -
Yes 3.33 1.81 – 6.12 < .001








Unknown 0.65 0.23 – 1.81 .411
Domestic status
Married / living with a partner REF - -
Environmental factors
 
 Single / widowed / divorced / 
separated
2.02 1.32 – 3.09 .001
Self-Efficacy (SEMCD)
Low confidence REF - -
Moderate confidence 0.42 0.24 – 0.73 .002





 Very confident 0.18 0.08 – 0.37 < .001
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<20 REF - -
≥20 (Clinical Level) 3.44 2.18 – 5.45 < .000
Anxiety (STAI-S)
<40 REF - -
≥40 (High Level) 1.82 1.15 – 2.87 .010
Social Support (MOS-SSS)
<100 (Not full) REF - -
=100 (Full) 0.41 0.23 – 0.74 .003
Health Status (EQ-5D-3L)





Perfect health 0.42 0.24 – 0.75 .003
NOTE
P-values in bold indicate a statistically significant difference at the 5% level. The model controls for the time point 
of the outcome report (post-surgery 3m to 60m), which was statistically significant.
Abbreviations: CES-D: Centre for Epidemiologic Studies Depression Scale; EQ-5D-3L: EuroQoL 5 Dimensions 3 Levels; 
MOS-SSS: Medical Outcome Study Social Support Scale; SEMCD: Self-Efficacy for Managing Chronic Disorders Scale; 
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Table 5: Multivariable logistic regression model of clinically significant depression (CES-D≥20) up 
to 5 years post-surgery, significant covariates collected at 2 years
Theme Block Covariates Odds Ratio 95% CI P
Accommodation type
Owner occupied REF - -
Socio-demographic factors
Rented / Other 2.38 1.23 – 4.62 .010
Affect (PANAS-SF)Personal factors
Negative Affect 1.21 1.08 – 1.36 .001
Depression (CES-D)
<20 REF - -
≥20 (Clinical Level) 3.14 1.41 – 7.04 .005
Health status (EQ-5D-3L)
Not perfect health REF - -
Perfect health 0.28 0.12 – 0.68 .005
Wellbeing (PWI-A)
≥70 (Good) REF - -
<70 (Poorer) 2.40 1.25 – 4.61 .008
Cognitive functioning (EORTC QLQ-C30)












 Some problem 2.21 1.03 – 4.77 .043
NOTE
P-values in bold indicate a statistically significant difference at the 5% level.
Abbreviations: CES-D: Centre for Epidemiologic Studies Depression Scale; EORTC-QLQ-C30: European Organisation 
for Research and Treatment of Cancer Quality of Life Core-30 Questionnaire; EQ-5D-3L: EuroQoL 5 Dimensions 3 











This article is protected by copyright. All rights reserved 
Appendix 1: Scoping review search strategy & key studies identified which involve people 
with CRC including at least one follow-up time point  
 
Dates literature searches conducted: 
 October 2016 
 August 2017 
 September 2018 
 May 2019 
 July 2019 
 October 2020 
 March 2021 
 
Databases searched:  
 CINHAL 
 APA PsycINFO 
 APA PsycARTICLES 
 MEDLINE (EBSCO) 
 ISI Web of Science 
 
Limiters: 
 Date published: 01/01/2010 to 01/10/2020 
 English language 
 Human studies 
 Peer-reviewed 
Search terms: 
Subject/MeSH Headings used where appropriate 
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(Colon OR Rectum) AND (neoplasms OR cancer) 
 
Depression OR MM Depression 





MH Stress, Psychological 





















Key findings Comparison to the 
ColoREctal Wellbeing 
(CREW) study 
Dunn et al., 
2013 (1) 
Australia 1,884 CRC 
survivors; 
stages I-IV 
T1: 5 months after 
diagnosis 
Follow-up: 12 (T2), 
24 (T3), 36 (T4), 48 






 Four trajectories of depressive 
symptoms: constant low levels, 
constant high levels, and people who 
increase from low and those who 
reduce from high levels. 
 Males, younger participants, later 
stage, poor social support and lower 
education were more likely to 
experience high levels of depression. 
 16.1% of participants were in the 
‘constant high’ level trajectory for 
depressive symptoms (BSI-18 
Depression subscale). 
 No pre-surgery 
assessment of 
psychological distress. 
 Recruitment of patients 
with metastatic CRC. 
Hart & Charles, 
2013 (2) 




Follow-up: T2: 6 
months, T3: 12 







 Mean (SD): T1: 10.45 (8.11), T2: 9.33 
(7.80), T3: 9.41 (8.74), T4: 9.49 (9.28) 
 Older adults reported lower levels of 
depressive symptoms. Men had fewer 
depressive symptoms than women. 
 The prevalence of clinical 
levels of depression was 
not assessed. 
 No follow-up assessment 























 Recruitment of patients 
with metastatic CRC. 
Gonzalez-Saenz 
de Tejada et al., 
2017 (3); 
Quintana et al., 
2018 (4) 






Follow-up: T2: 12 







 19.6% of participants reported 
depression at T1 
 Patients with depression improved 
less than participants not reporting 
depression or anxiety in all health-
related quality of life (QOL) domains 
(EORTC QLQ-C30) domains. 
 Overall, few differences in depression 
symptoms in people undergoing either 
open or laparoscopic surgery. 
 Mean (SD) [Laparoscopy vs Open]: T1: 
4.28 (4.12) vs 5.33 (4.84); T2: 3.52 
(3.85) vs 4.08 (4.31); T3: 3.50 (3.97) vs 
4.28 (4.38) 
 Recruitment of patients 
with metastatic CRC. 
 Recruitment of patients in 
relapse (CREW excluded 
patients with previous 
cancer diagnosis). 
 No follow-up assessment 
beyond 24 months post-
surgery. 
























to 4 years): T1: 
2010, T2: 2011, T3: 




depression (19.0%, N=2,625) 
compared to a matched population 
(12.8%, N=315) during their first 
assessment. 
 Reduction in depression symptoms 
over time with the largest difference 
identified when examining the first 
and fourth assessments (mean change 
-0.89). 
 Fewer depressive symptoms were 
reported in people who were older, 
low QOL and lower physical, role, 
cognitive, emotional and social 
functioning. 
4 years post-diagnosis. 
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Appendix 2: Availability of the covariates in two time points of the regression analyses 
Thematic Block Topic / Measure 
Taken time points in 








Age + + 
Gender +1 +1 
Ethnicity +1 +1 
Employment Status + + 
Accommodation type + + 
Index of Multiple Deprivation (IMD) +1 +1 
Clinical factors 
Tumour site + + 
Duke's stage + + 
Neoadjuvant treatment + + 
Adjuvant treatment - + 
Surgery type - + 
Stoma status - + 
Number of Comorbidities +2 + 
Previous use of mental health services + - 
Environmental 
factors 
Domestic status + + 
Life Events - + 
Medical Outcome Study Social Support Scale (MOS-SSS) + + 
Personal factors 
Self-Efficacy for Managing Chronic Disease 6-Item Scale 
(SEMCD) 
+ - 
Cancer Survivor Self-Efficacy Scale (CS-SES) - + 
Positive and Negative Affect Schedule Short Form (PANAS-SF) + + 
Psychosocial 
outcomes 
Centre for Epidemiologic Studies Depression Scale (CES-D) + + 
Quality of Life in Adult Cancer Survivors (QLACS) scale: 
QLACS Cancer-Specific Summary Score (QLACS-CSS) 
- + 
QLACS Benefit of Cancer subscale (QLACS-BC) - + 
State-Trait Anxiety Inventory - State scale (STAI-S) + + 
Personal Wellbeing Index - Adult (PWI-A) + + 
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Thematic Block Topic / Measure 
Taken time points in 





EORTC-QLQ-C30: Physical functioning - + 
EORTC-QLQ-C30: Emotional functioning - + 
EORTC-QLQ-C30: Cognitive functioning - + 
EORTC-QLQ-C30: Social functioning - + 
EORTC-QLQ-C30: Fatigue - + 
EORTC-QLQ-C30: Pain - + 
EORTC-QLQ-C30: Insomnia - + 
EORTC-QLQ-C30: Financial Worry - + 
KEY 
‘+’ included in regression analysis for time point 
‘-’ indicates excluded from regression analysis for time point due to measure not assessed at time point 
NOTE 
Data are taken from same time point unless otherwise annotated: 
1 
data taken from baseline time point, 
2 
data 
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Appendix 3: Self-Reported Health Service Use (Have you used any of the following health 
and social services in the last 12 months?) 
Time point 
(post-surgery) 






















2 (2.7) 0 (0) 2 (4.1) 1 (0.3) 3 (6.3) 1 (0.3) 1 (2.1) 1 (0.4) 
Counselling 
services 
4 (5.5) 2 (0.5) 6 (12.2) 2 (0.6) 2 (4.2) 5 (1.6) 1 (2.1) 2 (0.7) 
Psychiatrist 4 (5.5) 2 (0.5) 4 (8.2) 1 (0.3) 3 (6.3) 0 (0) 2 (4.3) 1 (0.4) 
Self-help 
group 
5 (6.8) 4 (1.0) 2 (4.1) 5 (1.5) 3 (6.3) 6 (1.9) 3 (6.4) 4 (1.5) 
NOTE 
Abbreviations: CES-D – Centre for Epidemiologic Studies Depression Scale 
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